Italian pharmacy online: cialis senza ricetta medica in farmacia.

Microsoft word - prostrakan sancuso eu launch press release 30.09.13.docx


ProStrakan Announces EU Launch of Sancuso

Galashiels, UK. 30th September 2013 - ProStrakan Group plc, the UK-based specialty pharmaceutical company, which is a subsidiary of Kyowa Hakko Kirin Co., Ltd., the Japan- based global specialty pharmaceutical company, announces that it has commenced the EU rol -out of its transdermal patch, Sancuso, for the prevention of chemotherapy-induced Sancuso is the first and only 5-hydroxytryptamine3 (5-HT3) receptor antagonist patch licensed for the treatment of chemotherapy-induced nausea and vomiting in multi-day chemotherapy for patients with swal owing difficulties. The transdermal patch is applied to the upper arm and can be worn for seven days, providing continuous transdermal delivery of granisetron. This eliminates the need for injections or daily pil s to control nausea and vomiting, a debilitating side effect that negatively impacts quality of life in cancer patients undergoing treatment. This simple-to-use treatment has been proven effective and tolerable in patients at risk of chemotherapy-induced nausea and vomiting. Sancuso has now been launched by ProStrakan’s own sales teams in the UK, Germany and the Netherlands, with additional EU countries planned for 2014. The launches fol ow the approval of Sancuso by the European Medicines Evaluation Agency (EMEA) in 2012. Sancuso was first launched in the US in 2008 and has been successful y marketed there Commenting on the start of Sancuso’s EU launches, Tom Stratford, Chief Executive of “The nausea and vomiting associated with some chemotherapy treatments can spel misery for some patients and, having proved a success in the US, we were keen to bring Sancuso to European patients and clinicians. “ProStrakan is a fast-growing business with a strategic focus on oncology-related products, in line with that of our parent company, Kyowa Hakko Kirin, and I am confident that the launch of Sancuso in the EU wil further advance our growth in this important Further enquiries:

About Sancuso (Granisetron Transdermal System)
SANCUSO transdermal patch is indicated in adults for the prevention of nausea and
vomiting associated with moderately or highly emetogenic chemotherapy, for a planned
duration of 3 to 5 consecutive days, where oral anti-emetic administration is complicated
by factors making swal owing difficult.

About ProStrakan
ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in
the development and commercialisation of prescription medicines for the treatment of
unmet therapeutic needs in major markets. ProStrakan is a subsidiary of Kyowa Hakko
Kirin Co., Ltd., the Japan-based global specialty pharmaceutical company. ProStrakan's
head office is located in Galashiels in Scotland. Sales and marketing of ProStrakan's
portfolio of products are handled by commercial subsidiaries in the UK, US, France,
Germany, Spain, Italy and other EU countries. You can learn more about the business at:
www.prostrakan.com

Source: http://www.u7293282.fsdata.se/pdf/prostrakan-sancuso-eu-launch-press-release-30.09.13.pdf

The link

The Link  A publication from the Alton Memorial Hospital Infection/Pharmacy Committee on Formulary and Drug Use Evaluation for physicians. March 2012 Medication Shortage Update There is currently a critical nationwide shortage of a number of commonly used injectables. One of these, potassium phosphate injection, is out of stock at Alton Memorial and there is no rel

Microsoft word - aut idem

Am Winkel 9a, 38 364 Schöningen/Hoiersdorf, Tel. 0 53 52 / 26 96, Fax 0 53 52 / 96 91 96 Sprechzeiten Montag bis Freitag 9 – 12 Uhr, Montag & Dienstag 15 – 18 Uhr, Donnerstag 15 – 19 Uhr „Das Kreuz mit dem Kreuz“ Seit einiger Zeit setzte ich auf Rezepten nur noch in Ausnahmefällen das so genannte „ Aut-idem-Kreuz “. Ich möchte im Folgenden die Gründe dafür

Copyright © 2010-2014 Pharmacy Drugs Pdf